Research Interests

• Acute myeloid leukemia (AML) accounts for 80% of adult acute leukemia, with the median age at diagnosis of 68 years. Chemotherapy has been the main therapeutic strategy for AML patients with poor prognosis in elderly patients (age 60 years and older). Differentiation therapy with relatively less severe side effects may benefit for elderly patients. However, all-trans retinoic acid (ATRA), a hallmark of successful differentiation therapy, is only effective in acute promyelocytic leukemia (APL), but not other subtype of AML. Therefore, we focus on discovering strategies to sensitize non-APL AML cells to ATRA and developing ATRA-based treatments for non-APL AML patients.